Entera Bio shares surge 10.83% after-hours on CEO insider purchase and preclinical data optimism.

Entera Bio Ltd. surged 10.83% in after-hours trading, driven by insider buying and preclinical data updates. The stock’s rally followed a purchase of 11,000 shares by Chief Executive Officer Miranda Jayne Toledano, signaling management’s confidence in the company’s prospects. Additionally, recent preclinical results for a once-daily oral treatment for hypoparathyroidism generated investor optimism, despite caution over early-stage data. While analyst downgrades and mixed hedge fund activity were noted, the positive signals from insider activity and clinical progress appeared to dominate, fueling the after-hours surge.